|
Demographics
|
|
Age
| | |
0.888
|
|
≤ 49 years
|
34 (21.3)
|
7 (4.4)
| |
|
50–59 years
|
32 (20.0)
|
8 (5.0)
| |
|
≥ 60 years
|
66 (41.3)
|
13 (8.1)
| |
|
Gender
| | |
0.643
|
|
Male
|
77 (48.1)
|
15 (9.4)
| |
|
Female
|
55 (34.4)
|
13 (8.1)
| |
|
Ethnicity
|
|
Malay
|
44 (27.5)
|
8 (5.0)
|
0.626
|
|
Chinese
|
57 (35.6)
|
11 (6.9)
| |
|
Indian
|
27 (18.1)
|
9 (5.6)
| |
|
Currently or previously smoking
|
34 (21.3)
|
7 (4.4)
|
0.934
|
|
Currently or previously consumed alcohol
|
19 (11.9)
|
4 (2.5)
|
0.988
|
|
Renal Replacement Therapy
| | |
0.750
|
|
Haemodialysis
|
52 (32.5)
|
9 (5.6)
| |
|
Peritoneal dialysis
|
10 (6.3)
|
2 (1.3)
| |
|
Conservative management
|
70 (43.8)
|
17 (10.6)
| |
|
Renal Function
| | |
0.041
|
|
30–59 mL/min/1.73m2
|
46 (28.7)
|
3 (1.9)
| |
|
15–29 mL/min/1.73m2
|
22 (13.8)
|
7 (4.4)
| |
|
< 15 mL/min/1.73m2
|
64 (40.0)
|
18 (11.3)
| |
|
Physical examinations
|
|
Systolic, mean (SD), mm Hg
|
132 (100)
|
28 (100)
|
0.486
|
|
Diastolic, median (IQR), mm Hg
|
132 (100)
|
28 (100)
|
0.159
|
|
Comorbid conditions
|
|
Diabetes
|
89 (67.4)
|
17 (60.7)
|
0.495
|
|
Dyslipidaemia
|
65 (40.6)
|
7 (4.4)
|
0.019
|
|
Hypertension
|
6 (3.8)
|
22 (13.8)
|
0.547
|
|
UTI
|
3 (1.9)
|
4 (2.5)
|
0.005
|
|
Laboratory data
|
|
Serum Albumin, mean (SD), g/L
|
132 (100)
|
28 (100)
|
< 0.001
|
|
Serum Alkaline Phosphatase, median (IQR), U/L
|
131 (99)
|
28 (100)
|
0.009
|
|
Serum Aspartate Aminotransferase, median (IQR), U/L
|
94 (71)
|
22 (79)
|
0.009
|
|
Serum CO2, mean (SD), mmol/L
|
116 (88)
|
26 (93)
|
0.020
|
|
Serum C-Reactive Protein, median (IQR), mg/L
|
62 (47)
|
23 (82)
|
< 0.001
|
|
Serum Lactate Dehydrogenase, median (IQR), U/L
|
94 (71)
|
23 (82)
|
< 0.001
|
|
Serum Low Density Lipoprotein (LDL), mean (SD), mmol/L
|
62 (50)
|
6 (21)
|
< 0.001
|
|
VMedications use
|
|
Total medication, median (IQR)
|
132 (100)
|
28 (100)
|
< 0.001
|
